Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome ELX-02 improved podocyte foot process effacement in all three treated patients by an average of 60% based on blinded biopsy analysis by NIPOKA GmbH Clinical data from Phase 2 study of ELX-02 for Alport Syndrome included in... Read More

ELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney biopsy analysis by NIPOKA GmbH Biopsy results support clinical benefit in all three patients as improvement of kidney morphology is consistent with reduction or stabilization of proteinuria during or... Read More

WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $5.255 per share (or common stock... Read More

Highly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans All three patients treated with ELX-02 showed a visual improvement in podocyte foot process effacement post-treatment in kidney biopsies demonstrating the disease modifying effect of ELX-02 Podocyte foot process effacement is a hallmark of... Read More

Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations Rebound in average UPCR 3-months post treatment provides further evidence that proteinuria remission in one out of three patients was drug related All 3 Alport patients (100% response rate) treated with ELX-02 had biopsy confirmed disease regression,... Read More

All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy demonstrating the disease modifying effect of ELX-02 Podocyte foot process effacement is a hallmark of Alport syndrome Together with previously announced rapid and sustained proteinuria remission in one patient in Phase 2 clinical study, these... Read More

Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy, demonstrating the disease-modifying effect of ELX-02 Announced achievement of remission in one patient in Phase 2 clinical study of ELX-02 for the treatment of Alport syndrome and decision to advance ELX-02 into a pivotal... Read More

WATERTOWN, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that it has determined to extend the exception granted on June 2, 2023 to Eloxx Pharmaceuticals, Inc. (the... Read More

Publication titled “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer” published in Cancer Research Communications Results suggest that MYC overexpressing cancers can be targeted by exploiting ribosome heterogeneity in cancer; preclinical data demonstrated activity of ZKN-157 against subtypes of colorectal cancer Research potentially... Read More

Alport syndrome is a rare progressive hereditary glomerular kidney disease caused by variants in COL4A and patients have significant unmet medical needs, with no disease modifying treatments currently available Eloxx announced additional results from its Phase 2 ELX-02 trial showing the patient that achieved a remission rebounded one month after withdrawing treatment, providing additional evidence of drug activity Eloxx... Read More

Globally renowned Alport syndrome experts will provide key insights Eloxx recently announced achievement of remission in one patient in its Phase 2 Alport syndrome clinical study and decision to advance into a pivotal trial in Alport syndrome WATERTOWN, Mass., June 21, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced... Read More

Data from RaDaR natural history study indicates that Alport syndrome patients with autosomal recessive COL4A4 mutations have severest disease, with a more rapid progression to kidney failure Patient that achieved remission in Eloxx Phase 2 trial had autosomal recessive COL4A4 nonsense mutation resulting in a truncated protein RaDaR registry data further supports decision to advance into a pivotal trial in Alport syndrome... Read More

ELX-02 trial results demonstrated clinically relevant improvement in percent predicted forced expiratory volume (ppFEV1) based on final data assessment; initial topline results were previously reported in September 2022 Efficacy of ELX-02 in CF study bolsters strength of recently announced results in Phase 2 Alport syndrome trial, further supporting Eloxx’s decision to advance into a pivotal trial in Alport syndrome... Read More

WATERTOWN, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the Nasdaq Hearings Panel has granted the Company’s extension request through July 30, 2023 to regain compliance with Nasdaq Listing Rule 5550(b)(2), which requires a listed company to have at least $35 million in market value of listed... Read More

Patient treated in trial achieved a remission after eight weeks of treatment, demonstrating a significant reduction in proteinuria ELX-02 well-tolerated in study, with no discontinuations to date WATERTOWN, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the company intends to advance ELX-02 into a... Read More

Topline results to include biopsy results for the Phase 2 clinical study evaluating ELX-02 for the potential treatment of Alport syndrome expected in first half of 2023; meaningful protein reduction has been observed in one patient to date Received U.S. Food and Drug Administration (FDA) clearance to begin a single ascending dose (SAD) clinical trial for ZKN-013 for the potential treatment of recessive Dystrophic... Read More

ZKN-013 is in development for potential treatment of recessive dystrophic and junctional epidermolysis bullosa (RDEB and JEB) and Familial Adenomatous Polyposis (FAP) ZKN-013 is Eloxx’s first drug candidate from its TURBO-ZM™ platform to gain clearance for clinical testing WATERTOWN, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) (“Eloxx” or the “Company”), a leader in ribosomal... Read More

Three patients now dosed in Phase 2 clinical study evaluating ELX-02 for the treatment of Alport syndrome; encouraging initial reduction in proteinuria has been observed in one patient to date Investigational New Drug (IND) application for ZKN-013 filed for treatment of recessive dystrophic epidermolysis bullosa (RDEB) WATERTOWN, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader... Read More

ZKN-013 in development for treatment of recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa (JEB) Additional IND filing for ZKN-013 for treatment of familial adenomatous polyposis (FAP) expected in first half of 2023 Recent preclinical results have provided additional support for ZKN-013 in RDEB and FAP WATERTOWN, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc.... Read More

WATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it will present at the Oppenheimer 33 rd Annual Healthcare Conference on Monday, March 13 th at 12:00 PM ET. A live webcast of the presentation and a replay of the presentation will be available on the Company’s website at... Read More

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the first patients have now been dosed in its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations. Topline results are expected in the first half of 2023. “Patients with Alport syndrome with... Read More

Topline results expected in first half of 2023 Trial sites open in Australia and United Kingdom WATERTOWN, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the first patients have now been enrolled in its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense... Read More